Elan, Biogen say new data confirm safety profile of Tysabri
Forbes - NY,USA
Extension study data showed that Tysabri has a sustained treatment effect on clinical relapses and the risk of disability progression in multiple sclerosis ...
See all stories on this topic

AFX News Limited
Elan, Biogen say new data confirm safety profile of Tysabri
05.03.07, 8:53 AM ET

LONDON (Thomson Financial) - Elan Corp PLC and Biogen Idec Inc said new data from the TOUCH prescribing program and TYGRIS safety study confirm the safety profile from previous clinical studies of its Tysabri multiple sclerosis drug.

Extension study data showed that Tysabri has a sustained treatment effect on clinical relapses and the risk of disability progression in multiple sclerosis patients treated for up to three years, the company said.

TFN.newsdesk@thomson.com

pmi/ro

COPYRIGHT

http://www.forbes.com/markets/feeds/afx/2007/05/03/afx3680982.html

Copyright AFX News Limited 2007. All rights reserved.

The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.

Neither the Subscriber nor AFX News warrants the completeness or accuracy of the Service or the suitability of the Service as a trading aid and neither accepts any liability for losses howsoever incurred. The content on this site, including news, quotes, data and other information, is provided by AFX News and its third party content providers for your personal information only, and neither AFX News nor its third party content providers shall be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon.

Biogen Idec: No new brain infections with Tysabri
Triangle Business Journal - Raleigh,NC,USA
Biogen Idec said Thursday that there have been no new cases reported of a potentially fatal brain infection associated with its drug Tysabri since the ...
See all stories on this topic